Triethylamine → N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-4-piperidinecarboxamide
Reaction equation
[CH3:1][C:2]1[N:7]=[C:6]([NH:8][CH3:9])[N:5]=[C:4]([N:10]2[CH2:15][CH2:14][CH:13]([C:16]([OH:18])=O)[CH2:12][CH2:11]2)[N:3]=1.CCN=C=N[CH2:24][CH2:25][CH2:26][N:27](C)C.C1[CH:31]=[CH:32][C:33]2N(O)N=[N:36][C:34]=2C=1.[CH2:40](N(CC)CC)C.BrC1C=CC(CN)=C(O[C:57]([F:60])([F:59])[F:58])C=1>ClCCl>[C:26]([C:25]1[CH:24]=[CH:40][C:33]([CH2:34][NH:36][C:16]([CH:13]2[CH2:12][CH2:11][N:10]([C:4]3[N:3]=[C:2]([CH3:1])[N:7]=[C:6]([NH:8][CH3:9])[N:5]=3)[CH2:15][CH2:14]2)=[O:18])=[C:32]([C:57]([F:60])([F:59])[F:58])[CH:31]=1)#[N:27]Participants
Reactant 5
Product 1
Reagents, catalysts & solvents 1
Procedure
1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-4-piperidinecarboxylic acid (100 mg, 0.4 mmol) was dissolved in 3 mL of dichloromethane and treated with EDCI (115 mg, 0.6 mmol), HOBt (65 mg, 0.48 mmol), triethylamine (0.44 mL, 3.2 mmol), and 1-{4-bromo-2-[(trifluoromethyl)oxy]phenyl}methanamine (152 mg, 0.4 mmol) at 8° C. for 4 days. The reaction mixture was concentrated and purified by preparative HPLC to provide N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-4-piperidinecarboxamide (3.5 mg, 0.02 mmol, 2%) as a white solid. MS (ES+): m/e 503, 505 [M+H]+. 1H NMR (400 MHz, methanol-D4) 7.4 (m, 2H), 7.2 (d, 1H), 4.8 (2H under MeOH peak), 4.3 (s, 2H), 3.1 (m, 2H), 2.9 (s, 3H), 2.5 (m, 1H), 2.3 (s, 3H), 1.8 (m, 2H), 1.6 (m, 2H)
Workup
- concentrationThe reaction mixture was concentrated
- custompurified by preparative HPLC
Sources & evidence
- ORD record
- ord-2f9191f159c344dfa7129a1fdd07100c
- Source dataset
- uspto-grants-2011_08
- Patent number
- US08008483B2
Reaction notes
Loading…